Neurological symptoms and axonal damage in COVID-19 survivors: are there sequelae?

Silvia Bozzetti¹ · Sergio Ferrari¹ · Serena Zanzoni² · Daniela Alberti¹ · Michele Braggio² · Sara Carta¹ · Francesco Piraino⁴ · Daniele Gabbiani⁵ · Domenico Girelli⁵ · Riccardo Nocini⁶ · Salvatore Monaco¹ · Ernesto Crisafulli⁵,⁷ · Sara Mariotto¹

Received: 9 May 2021 / Accepted: 23 July 2021 / Published online: 7 August 2021 © The Author(s) 2021

Abstract
The persistence of neurological symptoms after SARS-CoV-2 infection, as well as the presence of late axonal damage, is still unknown. We performed extensive systemic and neurological follow-up evaluations in 107 out of 193 consecutive patients admitted to the COVID-19 medical unit, University Hospital of Verona, Italy between March and June 2020. We analysed serum neurofilament light chain (NfL) levels in all cases including a subgroup (n = 29) of patients with available onset samples. Comparisons between clinical and biomarker data were then performed. Neurological symptoms were still present in a significant number (n = 49) of patients over the follow-up. The most common reported symptoms were hyposmia (n = 11), fatigue (n = 28), myalgia (n = 14), and impaired memory (n = 11) and were more common in cases with severe acute COVID-19. Follow-up serum NfL values (15.2 pg/mL, range 2.4–62.4) were within normal range in all except 5 patients and did not differentiate patients with vs without persistent neurological symptoms. In patients with available onset and follow-up samples, a significant (p < 0.001) decrease of NfL levels was observed and was more evident in patients with a severe acute disease. Despite the common persistence of neurological symptoms, COVID-19 survivors do not show active axonal damage, which seems a peculiar feature of acute SARS-CoV-2 infection.

Keywords Neurofilament · COVID-19 · NfL · Hyposmia · Hypogeusia · SARS-CoV-2

Introduction
A wide spectrum of neurological symptoms has been described in patients with novel SARS-CoV-2 infection. These include specific syndromes as encephalitis, neurovascular disorders, neuropathies, and muscular diseases as well as non-specific symptoms as headache, vertigo, fatigue, hyposmia, and hypogeusia [1, 2]. These data raised concerns about the possible occurrence of long-term neurological sequelae, supported by the persistence of hyposmia and hypogeusia.

Neurofilament light chain (NfL) levels are sensitive biomarkers of axonal damage, increased in patients with central and peripheral nervous system disorders [3]. An increase of serum or CSF NfL levels has been demonstrated also in subjects with acute SARS-CoV-2 infection, in particular in those with severe COVID-19 syndrome, with central neurological symptoms, and in patients with an unfavourable short-term outcome [4–7]. NfL levels are increased also in cases with mild to moderate COVID-19 and in patients
without evidence of neurological symptoms, further confirming the co-occurrence of neuronal damage in this condition [4, 8].

To detect the possible persistence of long-term neurological sequelae, we herein performed a clinical and biomarker follow-up study of patients with antecedent confirmed SARS-CoV-2 infection including also an extensive comparison with acute stage evaluations in a subgroup of patients.

**Patients and methods**

**Study subjects**

Consecutive patients \( (n = 193) \) with SARS-CoV-2 infection, confirmed by positive reverse transcriptase PCR of nasopharyngeal swab, were admitted to the COVID-19 medical unit of the University Hospital of Verona, Italy between March and June 2020. Among these, 107 patients without concomitant neurological comorbidities (i.e., cognitive impairment, cerebrovascular diseases, peripheral neuropathies) consented to a follow-up evaluation which included physical examination, respiratory tests, questionnaires related to the persistence on neurological specific and non-specific symptoms, and laboratory re-evaluation 6 months after symptoms onset and were therefore included in the present study. In 29 out of 107 included patients, both acute and follow-up clinical and biomarker data were available for comparison analyses.

**Clinical data and testing**

Demographic and clinical data were collected in each included case in a standardised form.

Lung function was analysed according to international recommendations. A flow-sensing spirometer connected to a computer (Jaeger MasterScreen PFT System) was used for the measurements. Forced vital capacity (FVC), forced expiratory volume in the first second \( (\text{FEV}_1) \), and total lung capacity (TLC) were recorded taking \( \text{FEV}_1/\text{FVC} \) ratio as index of airflow obstruction. Data concerning arterial blood gas analysis in term of arterial partial oxygen pressure \( (\text{PaO}_2) \) and arterial partial carbon dioxide pressure \( (\text{PaCO}_2) \) were also collected. Walking capacity was assessed by the distance covered at the 6-min walking test (6MWD). Individual’s perceived dyspnoea and fatigue at baseline and at end-effort of the 6-min walking test were measured with a 10-point modified Borg scale.

**NfL analysis**

Serum NfL levels were analysed in duplicates in all follow-up sera and in available paired onset sera by investigators blinded to clinical data using SIMOA Nf-light® kit in SR-X immunoassay analyser, Simoa™ (Quanterix Corporation, Billerica, MA, USA), as previously described [9]. Intra-assay coefficient of variation was <8%.

**Statistical analysis**

A preliminary Shapiro–Wilk test was performed. Data are reported with numbers (percentages) for categorical variables and mean (SD) or median [interquartile range] for continuous variables with a normal or non-normal distribution, respectively. Categorical variables were compared using the \( \chi^2 \) test or the Fisher exact test, while continuous variables were assessed using the independent \( t \)-test or the non-parametric Mann–Whitney \( U \) test or Wilcoxon test when appropriate. All analyses were performed using IBM SPSS, version 25.0 (IBM Corp., Armonk, NY, USA) and a \( p \)-value of <0.05 has been considered statistically significant.

**Results**

Among 107 included patients, 70 were males and median age was 63 years (range 32–90). During the acute COVID-19 phase, 16 patients required admission to ICU, mean C-reactive protein was 75.8 mg/L (SD 59.3), and mean P/F ratio was 279.86 (SD 78.5). None of these patients reported specific neurological symptoms suggestive for encephalitis, neurovascular disorders, neuropathies, and muscular diseases, while 37 subjects complained of hyposmia, 55 of hypogeusia, 11 of vertigo, 47 of fatigue, 20 of headache, 26 of myalgia, 7 of impaired consciousness, 6 of impaired memory, and 10 of syncope. Among patients with available onset and follow-up samples \( (n = 29) \), 14 cases had increased NfL levels in the acute stage in comparison with a group of healthy controls analysed in our laboratory \( (n = 60) \) whose NfL values are in agreement with those previously established for age-matched healthy controls [10]. In addition, NfL levels at onset did not show any correlation with gender and age.

On follow-up re-evaluation, 49 patients complained of the persistence of at least one possible neurological symptom (hyposmia, \( n = 11 \); hypogeusia, \( n = 7 \); vertigo, \( n = 6 \); fatigue, \( n = 28 \); headache, \( n = 4 \); myalgia, \( n = 14 \); impaired memory, \( n = 11 \)). Mean follow-up serum NfL value was 15.2 pg/mL (range 2.4–62.4) and only 5 patients had increased NfL values in comparison with healthy controls. None of these 5 patients reported hyposmia or hypogeusia but 3 of them had persistent fatigue.

No significant differences in functional biomarkers of respiratory outcome, age, body mass index (BMI), creatinine, serum C-reactive protein levels, and serum NfL levels were observed in patients with vs without persistent neurological...
symptoms. Interestingly, patients reporting at least one possible neurologic symptom at follow-up had experienced a significantly more prolonged duration of systemic COVID-19 (49.0 days vs 27.5, \( p < 0.01 \)). A significant correlation \( (p < 0.001) \) was noted between NfL levels obtained during the follow-up and age in absence of any correlation with gender.

A significant decrease \( (p < 0.001, \text{mean difference} 32.8 \text{pg/mL}, \text{standard deviation} 56 \text{pg/mL}) \) of NfL values was observed over time in patients with available onset and follow-up sera, as shown in Fig. 1. In particular, in 14 out of 29 patients, a 50% decrease of NfL levels was observed. In this subgroup of patients, a significant difference in terms of previous ICU admission \( (p < 0.001) \), BMI \( (p = 0.045) \), Borg scale dyspnoea at end-effort \( (p = 0.003) \), and duration of hospitalisation \( (p = 0.049) \) was observed. Notably, none of demographic, anamnestic, respiratory variables, and neurologic symptoms distinguished patients with a 50% decrease of serum NfL levels (Table 1).

### Discussion

To the best of our knowledge, our study is the first which explores the neurological sequelae of SARS-CoV-2 infection from a clinical and biomarker perspective after a consistent follow-up, set at 6 months to avoid the long-term effect of the acute neurological event on NfL values, in accordance with previous studies [11, 12].

Specific and non-specific neurological symptoms have been reported in patients with COVID-19 [1, 2] and different studies documented an increase of NfL levels during the acute phase of the infection, thus supporting the occurrence of concomitant acute axonal damage [4, 5, 7, 8]. In addition, despite the correlation between NfL values and the severity of the clinical picture in the acute stage [4, 6], the potential association between NfL values and long-term neurological sequelae is still unclear.

Our data reveal that only 4.6% of COVID-19 survivors display increased NfL levels over the follow-up, in contrast with the significantly higher percentage (57%) of patients with increased NfL values previously observed in the acute phase and herein confirmed [4]. In addition, NfL levels decrease over the follow-up in the vast majority of cases with available repetitive measurements. Then, a clear NfL/age correlation was noted only during recovery, thus emphasizing the significant impact of disease severity on NfL values in the acute phase. Our data are in agreement with previous studies on HIV-infected patients, where a reduction of NfL values to normal range over time, and in particular during antiretroviral therapy, has been described [13].

These observations do not support the persistence of axonal damage in COVID-19 survivors and retain significant clinical implications. Interestingly, despite this finding, almost half of patients herein analysed still complained of at least one non-specific neurological symptom. These self-reported symptoms do not correlate with the persistence of systemic/metabolic symptoms or signs but significantly correlate with the severity of acute SARS-CoV-2 infection, thus potentially reflecting the consequences of the acute event. In accordance, when analysing both onset and follow-up samples, the most significant NfL reduction occurs in patients having experienced a more severe acute disease (i.e. longer hospitalisation or ICU admission). In addition, neither follow-up NfL levels nor their reduction over time correlates with the persistence of non-specific neurological symptoms, thus not supporting a neurological nature of these symptoms. This finding is in agreement with previous studies reporting increased NfL levels during acute COVID-19 also in patients not reporting neurological symptoms, those suggesting the occurrence of a subclinical neuronal damage [4].

### Conclusions

COVID-19 survivors frequently complain of non-specific neurological symptoms but do not present a prolonged axonal damage. A substantial decrease of NfL values in comparison with onset levels is observed in this condition, and in particular in patients with a more severe acute event. Our study has some limitations including the small sample size of patients with available onset and follow-up sera and
the inability to obtain brain imaging data and to compare COVID-19-related complications with those observed in other infectious disorders. However, our data give further cues to clarify the nature of non-specific neurological symptoms and the possible persistence of long-term neurological sequelae.

Table 1  Comparison of serum NfL levels reduction in patients with available onset and follow-up evaluations

| Variables                              | Patients with ≥ 50% reduction of serum NfL levels (n = 14) | Patients with < 50% reduction of serum NfL levels (n = 15) | p value |
|----------------------------------------|------------------------------------------------------------|-----------------------------------------------------------|---------|
| Age, years                             | 62 ± 10.8                                                  | 70.6 ± 9.3                                                | 0.030   |
| Sex, male, n (%)                       | 11 (79)                                                    | 9 (60)                                                    | 0.427   |
| BMI, kg·m²                             | 28.7 [6.3]                                                 | 26.9 [1.9]                                                | 0.045   |
| Former smokers, n (%)                  | 6 (43)                                                     | 6 (40)                                                    | 0.876   |
| Arterial hypertension, n (%)           | 8 (57)                                                     | 10 (67)                                                   | 0.597   |
| Extensional dyspnoea, n (%)            | 3 (21)                                                     | 1 (6.7)                                                   | 0.330   |
| Hyposmia, n (%)                        | 1 (8.3)                                                    | 1 (6.7)                                                   | >0.999  |
| Hypogeusia, n (%)                      | 1 (8.3)                                                    | 1 (6.7)                                                   | >0.999  |
| Vertigo, n (%)                         | 2 (16)                                                     | 0 (0)                                                     | 0.188   |
| Fatigue, n (%)                         | 4 (33)                                                     | 4 (27)                                                    | >0.999  |
| Myalgia, n (%)                         | 3 (27)                                                     | 2 (13)                                                    | 0.620   |
| Impaired memory, n (%)                 | 4 (33)                                                     | 1 (6.7)                                                   | 0.139   |
| At least one neurologic symptom, n (%) | 7 (58)                                                     | 5 (33)                                                    | 0.194   |
| Other neurologic symptoms§, n (%)      | 4 (33)                                                     | 3 (20)                                                    | 0.662   |
| Symptoms duration, days                | 66 [100]                                                   | 27 [26]                                                   | 0.052   |
| Timespan between sampling and symp-     | 122 [121]                                                  | 124 [27]                                                  | 0.462   |
| toms resolution, days                  |                                                           |                                                           |         |
| C-reactive protein, mg/L               | 2 [4.5]                                                    | 1 [3]                                                     | 0.649   |
| FEV1, % pred                           | 126.4 ± 21.8                                               | 128.1 ± 22                                                | 0.835   |
| FVC, % pred                            | 127.5 ± 22.4                                               | 134.5 ± 24.1                                              | 0.441   |
| FEV1/FVC                               | 103.2 ± 8.5                                                | 100.2 ± 9                                                 | 0.371   |
| TLC, % pred                            | 103 ± 11.7                                                 | 104 ± 14                                                  | 0.841   |
| DLCO, % pred                           | 82.7 ± 16.6                                                | 94 ± 21.8                                                 | 0.140   |
| KCO, % pred                            | 88 ± 18.2                                                  | 97 ± 16.2                                                 | 0.180   |
| PaO₂, mmHg                             | 95.2 ± 9.4                                                 | 93.2 ± 19.6                                               | 0.731   |
| PaCO₂, mmHg                            | 38 [4]                                                     | 39 [3]                                                    | 0.642   |
| 6MWD, total distance covered           | 525 [214]                                                  | 530 [270]                                                 | 0.163   |
| 6MWD, % pred                           | 96.5 ± 16.5                                                | 100.2 ± 24.4                                              | 0.640   |
| Borg scale dyspnoea at end-effort*, score| 4 [3]                                                      | 1 [2]                                                     | 0.003   |
| Borg scale fatigue at end-effort*, score| 4 [4]                                                      | 1 [2]                                                     | 0.165   |
| SpO₂ at baseline, %                    | 97.3 ± 1.4                                                 | 96.8 ± 1.6                                                | 0.458   |
| SpO₂ at end-effort, %                  | 97 [3]                                                     | 96 [2]                                                    | 0.964   |
| Length of hospital stay, days          | 24 [21]                                                    | 11 [9]                                                    | 0.049   |
| Previous ICU admission, n (%)          | 10 (71)                                                    | 1 (6.7)                                                   | <0.001  |

Data are shown as mean ± standard deviation, median [interquartile range], or number (percentages). In bold, significant variables

Atrial fibrillation, ischemic heart disease, chronic heart failure, diabetes mellitus, chronic obstructive pulmonary disease, asthma, and chronic kidney disease have a prevalence of < 10% with no significant difference between groups

§Other self-reported symptoms included sleep disorders, paresthesia, and unspecific sight deficit

*The median of Borg scale at baseline was 0 in both groups

Abbreviations: BMI, body mass index; FEV₁, forced expiratory volume at 1st second; FVC, forced vital capacity; TLC, total lung capacity; DLCO, diffusion capacity for carbon monoxide; KCO, carbon monoxide transfer coefficient; PaO₂, arterial partial oxygen pressure; PaCO₂, arterial partial carbon dioxide pressure; 6MWD, 6-min walking distance; SpO₂, oxygen saturation by pulse oximetry; ICU, intensive care unit
Acknowledgements The authors thank Quanterix Corporation for providing assay assistance.

Author contribution SB: clinical data collection, data generation and interpretation, design and conceptualisation of the study, drafting the manuscript. SF: data generation and interpretation, design and conceptualisation of the study. SZ: biomarkers analysis, data generation and interpretation. MB, SC, DGa, Dgi, RN: sample and clinical data collection. FP: biomarkers data interpretation. SMo: design and conceptualisation of the study, revising the manuscript for intellectual content. EC: design of the study, sample and clinical data collection, data generation and interpretation, statistical analysis. SMA: design and conceptualisation of the study, clinical data collection, data generation and interpretation, biomarker analysis, drafting the manuscript. All authors read and approved the final manuscript.

Funding Open access funding provided by Università degli Studi di Verona within the CRUI-CARE Agreement. The study was partially supported by grant Brain Research Foundation Verona 2020 and ENACT from the Carveroundation, Italy.

Availability of data and material The data that support this study are available for sharing and further examinations from the corresponding authors (S.M.) on reasonable requests. The data are not publicly available because they contain information that could compromise patients’ consent.

Code availability Not applicable.

Declarations

Ethics approval The study was approved by the Ethics Committee of Verona University Hospital (prog. 2785CESC Verona-Rovigo).

Consent to participate/publication Informed consent was obtained from each included patient.

Conflict of interest S. Ferrari received support for attending scientific meetings by Shire, Sanofi Genzyme, and Euroimmun. F. Piraino is an employee of the Quanterix Corporation. S. Mariotto received speaker honoraria from Biogen. The other authors report no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767–83. https://doi.org/10.1016/S1474-4422(20)30221-0.
2. Piloto A, Benussi A, Libri I, et al. COVID-19 impact on consecutive neurological patients admitted to the emergency department. J Neurol Neurosurg Psychiatry. 2020;92:218–20. https://doi.org/10.1136/jnnp-2020-323929.
3. Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577–89. https://doi.org/10.1038/s41582-018-0058-z.
4. Mariotto S, Savoldi A, Donadello K, et al. Nervous system: subclinical target of SARS-CoV-2 infection. J Neurol Neurosurg Psychiatry. 2020;91:1010–2. https://doi.org/10.1136/jnnp-2020-323881.
5. Kanberg N, Ashton NJ, Andersson LM, et al. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology. 2020;95:e1754–9. https://doi.org/10.1212/WNL.0000000000010111.
6. Sutter R, Hert L, De Marchis GM, et al. Serum neurofilament light chain levels in the intensive care unit: comparison between severely ill patients with and without COVID-19. Ann Neurol. 2021;89:610–6. https://doi.org/10.1002/ana.26004.
7. Virhammar J, Niääs A, Fullmar D, et al. Biomarkers for CNS injury in CSF are elevated in COVID-19 and associated with neurological symptoms and disease severity. Eur J Neurol. 2020. https://doi.org/10.1111/ene.14703.
8. Ameres M, Brandstetter S, Toncheva AA, Kabesch M, Leppert D, Kuhle J, Wellmann S. Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19. J Neurol. 2020;267:3476–8. https://doi.org/10.1007/s00415-020-10050-y.
9. Mariotto S, Gajofatto A, Zuliani L, et al. Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis. J Neurol. 2019;266:1643–8. https://doi.org/10.1007/s00415-019-09306-z.
10. Hvid CVB, Knudsen CS, Parkert T. Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults. Scand J Clin Lab Invest. 2020;80:291–5. https://doi.org/10.1080/003655513.2020.1730434.
11. Tiedt S, Duering M, Barro C, et al. Serum neurofilament light: a biomarker of neuroaxonal injury after ischemic stroke. Neurology. 2018;91:e1338–47. https://doi.org/10.1212/WNL.0000000000006282.
12. Pujol-Calderón F, Portelius E, Zetterberg H, et al. Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke. Neurosci Lett. 2019;698:58–63. https://doi.org/10.1016/j.neulet.2018.12.042.
13. Ulfhammer G, Edén A, Mellgren Å, et al. Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment. AIDS. 2018;32:2171–8. https://doi.org/10.1097/QAD.000000000001950.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.